[Radiologic detection of triombrast in liposomes of liver and spleen (first phase of clinical trial)].
Clinical trials of the liposomal form of water-soluble x-ray contrast agent triombrast (90 mg of iodine in 1 ml) was carried out in 23 patients with Hodgkin's disease, 9 with liver cirrhosis, and 6 with malignant tumors of different localizations. Distinct images of the liver and spleen appeared 2-2.5 h after intravenous injection of the formulation. They could be observed during 4-6 h by plane radiography. Liposomal hepatolienography permits identification of the structural alteration sites 0.8-1.0 cm in size in these organs. Administration of higher doses of the formulation (more that 0.5 ml/kg) was associated with such side effects as fever and hyperthermia in 30% of patients parallel with the side effects common for iodine-containing x-ray contrast agents. These side effects could be eliminated by previous administration of prednisolone and pipolphen. These side effects were not observed after injection of lower doses of the formulation (less than 0.5 ml/kg) sufficient for an essential improvement of the image contrast during computer-aided tomography.